

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

**Myocardial-derived small extracellular vesicles spontaneously released from living myocardial slices under biomimetic culture conditions regulate contractility and cardiac remodelling**

L. Nicastro, A. Lal, A. Kyriakou, S. Kholia, R. Nunez Toldra, B. Downing, F. Kermani, M. Anwar, F. Martino, D. Chokron, P. Sarathchandra, M. Sarkar, C. Emanuelli, C.M. Terracciano\*

National Heart & Lung Institute, Imperial College London, London, UK

Short title: Myocardial -derived sEVs affect remodelling of failing hearts

\*Corresponding author:  
Prof. Cesare M. Terracciano  
Imperial College London, NHLI  
ICTEM building Hammersmith Campus,  
Du Cane Road,  
London W12 0NN, UK  
Email: [c.terracciano@imperial.ac.uk](mailto:c.terracciano@imperial.ac.uk)

28

29 **Abstract**

30 **BACKGROUND:**

31 Small extracellular vesicles (sEVs) released in the cardiac microenvironment are reported to  
32 regulate cardiac remodelling, partially via microRNA transfer. Harvesting sEVs produced  
33 exclusively from the myocardium remains challenging and a solid research platform for sEV  
34 cardiovascular testing needs to be established. Organotypic living myocardial slices (LMS)  
35 allow to mimic cardiac disease and to record electrophysiological responses to biological  
36 and pharmacological stimuli. This study aims at understanding how cardiac sEVs obtained  
37 from donor and failing human LMS and rat LMS under physiological or heart failure-  
38 mimicking conditions impact myocardial function and remodelling.

39

40 **METHODS & RESULTS:**

41 Human LMS were obtained from the left ventricle (LV) of human donor non-failing and end-  
42 stage failing hearts and cultured at 2.2  $\mu\text{m}$  sarcomere length (SL). Rat LV LMS from healthy  
43 Sprague-Dawley rats were cultured at a preload of 2.2 or 2.4  $\mu\text{m}$  SL, to recapitulate  
44 physiological load and overload, respectively. Following 48-hours biomimetic culture, sEVs  
45 were isolated from the culture media by size exclusion chromatography and characterized  
46 for their size, concentration, and expression of exosome markers. LMS from human failing  
47 hearts presented impaired contractility ( $P < 0.05$  vs donor-LMS), which was improved by  
48 application of donor heart-derived sEVs at 15 and 20% stretch. Whilst rat overloaded sEVs  
49 did not alter the force production of physiological LMS, physiological sEVs significantly  
50 increased the active force and decreased their passive force. In rat LMS,  $1 \times 10^8$  physiological  
51 EVs/slice restored the contractility of overloaded slices, reduced apoptosis, fibrosis-related  
52 gene expression and promoted angiogenesis. microRNAs analysis showed significant  
53 upregulation of miR-23a-3p and miR-378a-3p in rat physiological sEVs. Finally, to test  
54 whether sEVs have a direct effect on cardiomyocytes, we applied sEVs on cultured induced  
55 pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). sEVs did not affect the  
56 contractility of iPSC-CM monoculture but increased the contractility of iPSC-CM co-cultured  
57 with human microvasculature endothelial cells (MVECs).

58

59 **CONCLUSIONS:**

60 Cardiac sEVs isolated from healthy hearts increase the contractility of failing LMS. This effect  
61 is associated with, and possibly brought about by, a combination of inhibition of apoptosis,  
62 reduction of fibrosis and increased microvascular density, and could involve the transfer of  
63 sEV-microRNA into myocardial cells. Our data support the hypothesis that the sEV inotropic  
64 action is mediated by endothelial cells.

## 65 Introduction

66 Increased mechanical load caused by either excessive pressure or volume in the left  
67 ventricle is an important driver of cardiac remodelling. Multiple changes take place during  
68 remodelling caused by mechanical overload, such as development of hypertrophy,  
69 myocardial cells death, fibrosis, and blood vessel rarefaction. Over time these changes lead  
70 to ventricular dysfunction and ultimately heart failure<sup>1</sup>.

71 During both physiology and disease, cell-cell communication is responsible for driving  
72 cellular and molecular changes to respond to changes in the environment<sup>2,3</sup>. Numerous  
73 mechanisms of cell-cell communication, from direct contact to the release of soluble  
74 paracrine and endocrine factors, have been extensively investigated and are known to be  
75 important mediators of both cardiac homeostasis and remodelling.

76 Extracellular vesicles (EVs) encompass several types of nanosized and micro-sized vesicles  
77 with a lipid bilayer membrane and bioactive cargoes, including nucleic acids, proteins, lipids  
78 and metabolites<sup>4</sup>. Small EVs (sEVs), also known as exosomes, have been already recognized  
79 as important mediators of intercellular and extracellular communications in the  
80 cardiovascular system<sup>5</sup>. Both proteins and microRNAs (miRNAs) have been found to mediate  
81 cellular responses induced by sEVs, including cardiac remodeling and cardiac protection<sup>6, 7, 8,</sup>  
82 <sup>9</sup>. Despite the interest for sEVs in cardiovascular research, the understanding of the role of  
83 endogenous cardiac sEVs in the local microenvironment has been so far hindered by the lack  
84 of appropriate research models. Previous *in vitro* and *in vivo* studies have adopted sEVs  
85 prepared from either complex and non-cardiac specific samples, such as the human  
86 plasma<sup>10</sup>, or cultured cells, which are unable to recapitulate the complexity of the  
87 myocardium, making most studies of low translational value<sup>2</sup>.

88 Living myocardial slices (LMS) are 300 µm thin layers of ventricular myocardial tissue that  
89 can be obtained from human heart of donors and heart failure patients and, also, from  
90 different small and large animal species<sup>11</sup>. LMS not only retain the multi- and hetero-  
91 cellular composition, the electrophysiology, and the extracellular matrix of the adult  
92 myocardium, but also possess the ability to long term culture while performing physiological  
93 functions, the ability to be manipulated in a specific and controlled manner by various  
94 stimuli, and the capacity to be studied for cellular and molecular mechanisms<sup>11-13</sup>.  
95 Noteworthy, pathological stimuli known to affect cardiac remodelling and sEVs biology, such  
96 as mechanical overload, can be reliably reproduced in LMS<sup>14-16</sup>.

97 In this study, we have employed LMS to isolate and characterize sEVs released from human  
98 donors and failing hearts. We have complemented the human studies with analyses of rat  
99 LMS subjected to different degrees of mechanical load to investigate the effects of cardiac-  
100 derived sEVs on the regulation of cardiac contractility and structural and molecular  
101 overload-induced myocardial remodelling.

## 102 Methods

103 Methods are described in detail in the Supplemental Material.

## 104 *Ethical statements for the use of human and rat hearts*

105 Human failing hearts were obtained from the NIHR Cardiovascular Biomedical Research Unit  
106 at the Royal Brompton and Harefield NHS Foundation Trust and Imperial College London.  
107 The study was approved by a UK institutional ethics committee (NRES ethics number for  
108 biobank samples: 09/H0504/104 + 5; Biobank approval number: NP001-06-2015 and  
109 MED\_CT\_17\_079) and Imperial College London.

110 Human donor hearts were obtained from the NHS Blood and Transplant INOAR program  
111 (IRAS project ID: 189069) approved by the NHS Health Research Authority, in accordance  
112 with the Governance Arrangements for Research Ethics Committees. This study is fully  
113 compliant with the Standard Operating Procedures for Research Ethics Committees in the  
114 UK. Informed consent was obtained from each patient/family involved in this study.

115 All experiments performed on animals were approved by the UK Home Office, in accordance  
116 with the United Kingdom Animals (Scientific Procedures) Act 1986 and Amendment  
117 Regulations 2012; killing procedures were performed in accordance with the established  
118 guidelines of the European Directive on the protection of animals used for scientific  
119 purposes (2010/63/EU). The investigation conforms to the Guide for the Care and Use of  
120 Laboratory Animals published by the US National Institutes of Health (NIH Publication No.  
121 85-23, revised 1985) and to the principles outlined in the Declaration of Helsinki (Br Med J  
122 1964; ii: 177).

## 123 **Statistical analysis**

124 All data are expressed as mean  $\pm$  standard error of the mean. Data were analysed using  
125 GraphPad Prism 9 software. To assess normality, Shapiro-Wilk's test was used. For multiple  
126 groups comparisons of normally distributed data where unpaired samples were used, such  
127 as contractility data in physiological, overloaded and EVs treated LMS at different stretch  
128 increments, two-way ANOVA was used, followed by Tukey's multiple comparison test. For  
129 multiple groups comparison of normally distributed data where paired samples were used,  
130 such as contractility data in human failing LMS treated with donor sEVs and untreated,  
131 multiple paired t-test was used, as control and treated preparation were handled in parallel.  
132 To measure sEVs particle size distribution in human and rat samples, the area under the  
133 curve for the particle size distribution was calculated, and an unpaired 2-tail t-test  
134 performed, using the average concentration, SEM and N number for the respective  
135 conditions, which were previously calculated in the area under the curve analysis. For  
136 experiments assessing remodelling aspects in physiological, overloaded and EVs treated  
137 LMS, one-way ANOVA was used followed by Tukey's multiple comparison test. Kruskal  
138 Wallis test and Dunn's multiple comparison test were used when data were not normally  
139 distributed. 2-tailed student t-test was used to compare the treated versus non-treated  
140 groups in iPSC-CMs-only and co-culture experiments.

141

## 142 **Results**

143 **Active force in human failing LMS is significantly lower compared with human donor LMS**

144 All human donor and failing LMS were cultured at a SL of 2.2  $\mu\text{m}$ . To investigate  
145 contractility, we performed a force-stretch relationship experiment after 48 hours of  
146 culture. As shown in Figure 1 A and B, donor LMS generated a larger force upon stimulation  
147 compared with failing LMS; there was no significant change in passive force (Figure 1C).

#### 148 **Human failing sEVs are more abundant compared to human donor EVs**

149 Cardiac sEVs were extracted from the supernatant of donor and failing LMS culture. The sEV  
150 particle-size distribution and concentration were analysed by Nanoparticle Tracking  
151 Analysis. The analysis showed a higher concentration of sEVs/ml from the failing heart,  
152 compared to the donor heart (Figure 1 D). The sEV identity was confirmed by tetraspanin  
153 (CD63, CD81 and CD9) chips for sEV capture and imaging on the ExoView™ R100 imaging  
154 platform (NanoView Biosciences). As shown in Figure 1 E, the human sEVs expressed all  
155 three tetraspanins <sup>17</sup>, in different quantities, with CD81 being the most abundant  
156 (Supplementary figure 1 B). Transmission electron microscopy with immunogold-labelled  
157 antibodies targeting the human CD63 tetraspanin marker further confirmed the successful  
158 enrichment of sEVs secreted by human LMS (Figure 1 F).

159

#### 160 **Human sEVs released by the donor LMS increase the active force produced by human** 161 **failing LMS**

162 Given the biological relevance of cardiac sEVs isolated from the human donor LMS, we  
163 sought to investigate whether these sEVs affect cardiac contractility of human failing LMS.  
164 We observed that failing human LMS cultured with  $10^9$  donor sEVs, which corresponded to  
165 the number of particles released from an individual human donor LMS after 48 hours, had  
166 increased contractility compared with their untreated counterpart (Figure 2 A). In fact, the  
167 active force of failing LMS treated with donor sEVs was significantly higher at 15 and 20%  
168 stretch compared with non-treated LMS, whilst no change in passive force was observed  
169 (Figure 2 B and C).

#### 170 **Active force production in rat physiological LMS is higher compared with overloaded LMS**

171 To recreate physiological load and overload, we stretched rat slices uniaxially in order to  
172 obtain a SL of 2.2 and 2.4  $\mu\text{m}$ , respectively (Figure 3 A, from <sup>14</sup>). Following 48 hours of  
173 culture, we observed that physiological and overloaded LMS exhibited a different contractile  
174 phenotype (Figure 3 B). Figure 3 C shows that physiological LMS generated significantly  
175 higher active force from 5 to 25% stretch, compared with the overloaded LMS. The passive  
176 force did not change significantly between the two conditions (Figure 3 D).

#### 177 **Rat overloaded LMS secrete an equal amount of sEVs to physiological LMS but the sEVs** 178 **contain more proteins**

179 A particle-size distribution analysis revealed a similar concentration of sEVs released from  
180 overloaded LMS compared to physiological LMS (Figure 3 E and supplementary figure 1 A).  
181 However, measurements of internal protein content of sEVs revealed a higher amount of  
182 protein in the sEVs from overloaded LMS, when compared to physiological LMS (Figure 3 F).  
183 Electron microscopy with CD63 immunogold labelling confirms the presence of rat sEVs

184 (Figure 3 G). Given the more immediate availability of rat hearts, the following functional,  
185 structural, and molecular studies were performed on rat LMS and rat LMS-derived sEVs.

### 186 **Physiological cardiac sEVs increase the active force and decrease the passive force of** 187 **physiological LMS**

188 Both physiological and overloaded sEVs were applied on rat physiological LMS to assess  
189 whether sEVs would mediate changes in contractility on healthy tissue (Figure 4 A). Force-  
190 stretch relationship of physiological LMS treated with either PBS vehicle, physiological sEVs  
191 or overloaded sEVs revealed that physiological sEVs increase the active force of  
192 physiological LMS at 25% and 30% stretch (Figure 4 B) and decrease the passive force from 0  
193 to 20% stretch (Figure 4 C). However, the application of overloaded sEVs on physiological  
194 LMS had no significant effect on the production of both active and passive force, compared  
195 to untreated physiological LMS (Figure 4 B and C).

### 196 **Physiological cardiac sEVs increase the active force of overloaded LMS in a dose-response** 197 **manner**

198 To assess the functional effect of rat physiological sEVs on the overloaded LMS,  
199 concentrations ranging from  $10^7$  to  $10^{10}$  were tested (Figure 4 D). We observed that the  
200 minimum amount of sEVs per LMS required to achieve a significant increase in active force  
201 was  $1 \times 10^8$  sEVs (Figure 4 E). However, no significant difference was observed in the passive  
202 force of overloaded rat LMS treated with physiological sEVs (Figure 4 F). The following  
203 structural and molecular experiments to assess cardiac remodelling were performed using  
204  $1 \times 10^8$  sEVs.

### 205 **Application of physiological cardiac sEVs does not affect the size of cardiomyocytes in** 206 **overloaded LMS**

207 In a condition of volume overload, eccentric hypertrophy develops, where the  
208 cardiomyocytes elongate, and sarcomeres are added in series<sup>18</sup>. In our model of uniaxial  
209 mechanical overload, we saw a significant elongation of the cardiomyocytes, compared to  
210 the physiological condition (Supplementary figure 2 A). This resulted in an overall increase  
211 of the cardiomyocytes area, whilst no difference was observed in the width (Supplementary  
212 Figure 2 B and C). The application of physiological sEVs on overloaded slices did not change  
213 cell size (Supplementary Figure 2 D).

### 214 **Application of physiological cardiac sEVs attenuates the transcriptional expression of** 215 **profibrotic genes in overloaded LMS**

216 The development of fibrosis following mechanical overload is an important determinant of  
217 cardiac contractility<sup>19</sup>. Production and deposition of collagens in the ECM and proliferation  
218 of stromal cells are crucial factors in the identification of cardiac fibrosis. Therefore, we first  
219 examined the amount of Collagen I and Vimentin deposition through immunostaining  
220 (Figure 5 A); no difference was observed between physiological and overloaded LMS (Figure  
221 5 B and C, respectively). The expression of Collagen I was also studied at protein level, along  
222 with the protein  $\alpha$ -smooth muscle actinin ( $\alpha$ -SMA), to assess fibroblasts activation. No  
223 significant change was observed in the expression of Collagen I (Figure 5 D) and  $\alpha$ -SMA



224 (Figure 5 E) between physiological and overloaded slices. Likewise, the application of  
225 physiological sEVs on overloaded slices did not have any effect on fibrosis development at  
226 either structural or protein level. However, when we analysed expression of some of the  
227 fibrosis-related genes by q-RT-PCR, we observed increased levels of  $\alpha$ -SMA, Fibronectin,  
228 TGF- $\beta$ , Collagen I and SMAD3 in the overloaded LMS, compared with physiological.  
229 Application of physiological sEVs on overloaded slices prevented/reversed the activation of  
230 Fibronectin, TGF- $\beta$  and SMAD3 (Figure 5 F).

### 231 **Application of physiological cardiac sEVs reduces cell death in overloaded LMS**

232 To assess cell death, another possible determinant of reduced cardiac contractility<sup>20</sup>, we  
233 first measured the level of cleaved PARP-1. PARP-1 is cleaved when it gets activated during  
234 apoptosis<sup>21</sup>. Cleaved PARP-1 was increased in overloaded LMS compared with physiological  
235 LMS. Moreover, upon application of physiological sEVs, the cleavage of PARP-1 was reduced  
236 to almost physiological levels (Figure 6 A). Bcl-2 is a potent pro-survival protein. Whilst its  
237 expression was maintained at basal level in physiological and overloaded slices, the level of  
238 Bcl-2 increased following application of sEVs on overloaded LMS. These data suggest that  
239 sEVs activate pro-survival pathways in the slices subjected to increased mechanical load  
240 (Figure 6 B).

241 Cell death in the LMS was further investigated by TUNEL staining. Transversal LMS  
242 cryosections showed increased TUNEL positive nuclei mostly on the surface of overloaded  
243 LMS, compared with physiological LMS. Application of physiological sEVs on overloaded LMS  
244 reduced the abundance of TUNEL positive nuclei to almost physiological levels (Figure 6 C).

### 245 **Application of physiological cardiac sEVs reduces microvascular rarefaction in overloaded LMS**

247 Heart failure is associated with microvascular rarefaction<sup>22,23</sup>. In our study, Isolectin B4  
248 staining confirmed reduced microvascular density in the overloaded LMS compared with  
249 physiological slices. Application of physiological sEVs in overloaded slices partially prevented  
250 this phenomenon (Figure 7 A) and increased the mRNA expression of VEGF-A, a prototypical  
251 proangiogenic and angiocrine factor (Figure 7 B).

### 252 **Exogenous cardiac sEVs preferentially localize around the nuclei of non-cardiomyocytes in the recipient LMS**

254 We first performed sEV incorporation studies at 1, 24 and 48 hours using ExoGlow-stained  
255 sEVs to understand the time course of sEV uptake. We observed the presence of sEVs on the  
256 surface of LMS at 1- and 24-hours, but this was reduced at 48-hours (Supplementary Figure  
257 3 A), suggesting that after 48 hours of incubation, sEVs are mostly internalised by the LMS.  
258 To assess the biodistribution of sEVs, we performed experiments using the 24-hours  
259 timepoint, to quantify the presence of sEVs on the cells surface at their maximum visibility.  
260 We observed that sEVs were preferentially localized around the nuclei of non-  
261 cardiomyocytes: 19.3% of the total nuclei of vimentin-positive cells, and only 5.76% of  $\alpha$ -  
262 actinin-positive cells were co-localised with sEVs (Supplementary Figure 3 B).

263 **Physiological cardiac sEVs contain higher level of microRNA-378a-3p and -23a-3p in**  
264 **comparison with pathological sEVs**

265 To investigate differences in miRNAs cargo between physiological and overloaded rat sEVs,  
266 we performed a miRNA array to assess the expression of 372 miRNAs which are conserved  
267 between rat and human species. We found two miRNAs (miR), miR-378a-3p and hsa-miR-  
268 23a-3p, to have higher expression in physiological compared with overloaded sEVs. By  
269 contrast, miR-16-5p and miR-346, were significantly increased in the overloaded sEVs  
270 (Supplementary Figure 4 A and B). We focussed on the upregulated miRNAs in physiological  
271 sEVs, as these could directly repress the expression of their target genes in overloaded LMS.  
272 miRNA qPCR analysis confirmed the upregulation of miR-378a-3p and miR-23a-3p in  
273 physiological sEVs compared with overloaded sEVs (Supplementary Figure 4 C and D).

274 **Bioinformatics analysis reveals potential mRNA targets of miR-378a-3p and miR-23a-3p**  
275 **that are increased in cardiomyocytes extracted from overloaded LMS**

276 We performed a bioinformatics analysis to find potential target genes for miR-378a-3p and  
277 hsa-miR-23a-3p. Predicted targets of miR-378a-3p and hsa-miR-23a-3p were cross-  
278 referenced with genes that were significantly differentially expressed in cardiomyocytes  
279 isolated from overloaded LMS, compared to physiological (Supplementary Figure 5 A). Six  
280 target genes, Gadd45g, Slc4a11, Xirp2, Dusp13, Usp13 and Triadin, were identified, which  
281 were overexpressed in overloaded cardiomyocytes and regulated by miR-378a-3p and hsa-  
282 miR-23a-3p (Supplementary Figure 5 B and C). Pathway analyses performed on these genes  
283 revealed their possible involvement in cardiac contractility and apoptosis (Supplementary  
284 Figure 5 D).

285 **Physiological cardiac sEVs do not regulate the contractility of human cardiomyocytes**  
286 **monocultures.**

287 Given the interplay between different cardiac cells in the LMS, it is challenging to assess  
288 whether cardiomyocytes are directly affected by sEVs to increase cardiac contractility. To  
289 address this issue, we employed human iPSC-CMs that express the calcium indicator  
290 GCaMP6f<sup>24</sup>, to simultaneously assess the impact of cardiac sEVs on calcium handling and  
291 cardiomyocyte contractility (Figure 10 A and B). iPSC-CMs were seeded on 7 mm diameter  
292 MatTek dishes at a density of 80,000 cells per dish for 48 hours and treated with 10<sup>9</sup> sEVs or  
293 PBS control. Calcium handling and contractility were assessed and compared between sEVs-  
294 treated and untreated (PBS only) iPSC-CMs. There was no significant difference in the  
295 amplitude of calcium transients between sEV-treated iPSC-CMs and controls (Figure 10 C).  
296 Nevertheless, the iPSC-CMs time to peak of the calcium transients was increased after sEV-  
297 treatment (Figure 10 D). The time to 50% and 80% decay remained unchanged between the  
298 2 conditions (Figure 10 E and F). Likewise, the amplitude of iPSC-CM contractility was not  
299 different in sEV-treated and control iPSC-CMs (Figure 10 G).

300 **Physiological cardiac sEVs increase contractility of iPSC-CM co-cultured with endothelial**  
301 **cells**



302 Given the increased VEGF-A and vascular response observed in overloaded LMS treated with  
303 physiological cardiac sEVs (Figure 7 A and B), and the prevalent non-CM distribution of  
304 exogenous sEVs in recipient LMS (supplementary Figure 3 B), we hypothesised the  
305 importance of endothelial cells for the CM response to sEVs. We therefore co-cultured  
306 iPSC-CMs with human coronary microvascular endothelial cells (MVECs) before sEVs  
307 application (Figure 10 H and I). Physiological cardiac sEVs did not affect calcium handling  
308 parameters compared to control (Figure 10 J-M). However, cardiac sEV increased the  
309 contractility of iPSC-CM co-cultured with MVEC (Figure 10 N).

## 310 Discussion

311 We report the successful isolation and characterisation of sEVs secreted from the  
312 ventricular myocardium of human failing and donor healthy hearts and from rat LMS  
313 cultured under physiological and overloaded conditions. Our protocols open unprecedented  
314 possibilities for the characterization of the cardiac sEVs in the cardiac microenvironment.

315 This study has demonstrated that cardiac sEVs released from the human donor hearts  
316 increase the contractility of failing LMS. Moreover, rat physiological sEVs increase  
317 contractility of both physiological and overloaded LMS, at a minimum concentration of  $10^8$   
318 particles/LMS. In contrast, sEVs released from the rat overloaded LMS had lost the capacity  
319 to regulate contractility.

320 We have showed that overload reduces LMS contractility, increases the expression of  
321 profibrotic genes, reduces cell survival and induces microvascular rarefaction, simulating the  
322 feature of failing myocardium. Importantly, these pathogenic features are repressed by  
323 stimulating the LMS with rat physiological cardiac sEVs, thus suggesting that sEVs released  
324 from healthy hearts contribute to preventing and possibly reversing, pathological cardiac  
325 remodelling.

326 HF with reduced ejection fraction (HFrEF) is characterised by lower muscle contractility. In  
327 clinical cases of HF, there is a downward shift in the Frank-Starling curve, which correlates  
328 with the inability of the heart to work effectively<sup>28</sup>. LMS are an ideal *ex vivo* platform to  
329 study myocardial contractility because they retain the electrophysiology and multicellularity  
330 of the adult myocardium<sup>29</sup>. Here we show that human failing LMS shifted the Frank Starling  
331 curve downwards compared with donor LMS, in accordance with what is observed clinically  
332<sup>30,31</sup>.

333 By applying different degrees of mechanical load on rat LMS, we were able to induce a  
334 distinct contractile phenotype, similar to what was observed in the human slices. This  
335 finding has been previously reported by us in<sup>14,32</sup>. For instance, we experimentally  
336 determined the best SL to culture LMS for 24 hours, and found that slices cultured at 2.2  $\mu\text{m}$   
337 maintained the same viability, gene expression and minimal change in force compared to  
338 fresh slices, where contractility was measured immediately after slicing<sup>14</sup>. We reported a  
339 significant difference in the amplitude of maximum contractility between rat slices cultured  
340 at 2.2 and 2.4  $\mu\text{m}$  after 48 hours. The significant decrease in force produced by the  
341 overloaded slices was associated with an increase in Collagen I deposition and the  
342 overexpression of major profibrotic genes<sup>32</sup>. While 48-hour culture might not be sufficient

343 to induce a complete remodelling of the LMS *in vitro*, the rat overloaded LMS recapitulate  
344 several features of human failing myocardium.

345 Native sEVs are considered for their potential to regulate cardiac homeostasis. This is in line  
346 with the knowledge that sEVs isolated from specific cardiac cell types contain cargoes that  
347 can confer cardioprotection in a damaged heart<sup>33</sup>; however, the effects of cardiac sEVs  
348 released from the myocardial tissue remain untested. In this study, we demonstrate that  
349 LMS release sEVs; we show the ability of healthy sEVs derived from the human and rat  
350 hearts to restore contractility and partially reverse/prevent remodelling after cardiac  
351 damage<sup>35–38</sup>.

352 In our study, despite observing a significant difference in sEV release between human failing  
353 and donor LMS, we showed that there was no difference in the concentration of sEVs  
354 released by either rat overloaded or physiological LMS after 48 hours culture. However,  
355 overloaded LMS-derived sEVs did not significantly affect the production of either active or  
356 passive force in physiological slices, in clear contrast with physiological sEVs, suggesting that  
357 the formulation of the sEVs derived from physiological and pathological is different. In line  
358 with this, we recorded different levels of total protein content between overloaded and  
359 physiological sEVs.

360 Several studies have shown that sEV actions are mediated by miRNA transfer<sup>39,40</sup>.  
361 Therefore, the beneficial effects of cardiac sEVs may be mediated by miRNA transfer. In line  
362 with this hypothesis, we found increased expression of miR-378a-3p and hsa-miR-23a-3p in  
363 the physiological cardiac sEVs when compared with the sEV from rat overloaded LMS. These  
364 miRNAs have been previously shown to repress cardiac hypertrophy<sup>41</sup> and apoptosis<sup>42</sup> and  
365 to promote angiogenesis<sup>45</sup>. A limitation of our miRNA array approach is that it contained a  
366 limited number of miRNAs selected for their conservation between humans and rats.  
367 Alternative miRNA candidates might emerge in future studies based on RNA-sequencing  
368 approaches.

369 A miRNA canonical mechanism of action is to repress the expression of a pool of targeted  
370 genes acting at post-transcriptional level by binding to the 3'UTR of mRNAs<sup>46</sup>. In line with  
371 this, bioinformatic target prediction revealed that potential target genes of miR-378a-3p  
372 and hsa-miR-23a-3p were involved in the regulation of cardiac contractility and apoptosis of  
373 cardiomyocytes.

374 Excessive mechanical preload of the heart results in the development of eccentric  
375 hypertrophy, where cardiomyocytes elongate through the addition of sarcomeres in series  
376<sup>47</sup>. In our model of mechanical overload, we observed a significant elongation of  
377 cardiomyocytes compared to the physiological counterpart. The addition of sarcomeres in  
378 series leads to a decrease in force being generated by the cardiomyocytes, as to reach an  
379 optimal SL, longer cardiomyocytes may need to be stretched more, compared to shorter  
380 cardiomyocytes containing less sarcomeres<sup>48</sup>.

381 In our study, we found that after 48 hours of culture under overloaded conditions, the  
382 process of fibrosis activation is only initiated at transcriptional level, with no significant  
383 changes at protein and structural level. However, physiological sEVs were able to inhibit the

384 overexpression of the major pro-fibrotic genes in overloaded slices. A previous study on  
385 fibrosis conducted on LMS showed that, although there was a significantly higher Collagen I  
386 deposition in overloaded slices after 48 hours compared with the physiological controls, the  
387 difference in the amount of stromal cells proliferation on the slices was unchanged<sup>15</sup>.  
388 Moreover, the changes in Collagen I were only seen with immunofluorescence staining and  
389 could not be detected by western blot analysis.

390 The cleavage of PARP-1 is a hallmark of cell death<sup>49</sup>. In our study, we observed a significant  
391 increase in cleaved PARP-1 in the overloaded slices compared with the physiological LMS.  
392 TUNEL staining revealed that cell death was prevalently localized on the surface of the  
393 myocardial slices. During LMS preparation, the blade cutting along the surface of the tissue  
394 damages ~3% of the total LMS cells, and only on the surface of the slice, leaving the rest of  
395 the preparation intact<sup>11</sup>. We speculate that surviving cells on the LMS surface are more  
396 fragile and sensitive to the detrimental actions of overload. Physiological sEVs were able to  
397 inhibit the process of cell death on overloaded slices. However, because changes in cell  
398 death were limited to the LMS surface, is unlikely that prevention of cell death by the  
399 healthy sEVs is the only contributor to the increase in contractility produced by these sEVs.

400 Microvessels rarefaction is a hallmark of cardiac remodelling and reportedly contributes to  
401 HF with preserved ejection fraction (HFpEF)<sup>50</sup>. Microvessels are tasked not only to  
402 constantly deliver oxygenated blood and nutrients to cardiomyocytes, but also act as a  
403 source of paracrine regulatory molecules that help in the modulation of cardiac contractility  
404<sup>51</sup>. In the overloaded slices, we observed a significant loss in microvessels. It is worth noting  
405 that vessels are not perfused in LMS, therefore regulation of cardiomyocyte contractility is  
406 likely to occur through direct contact and/or paracrine interactions. VEGF was maintained at  
407 basal levels in physiological and overloaded conditions but, upon application of sEVs, these  
408 levels raised significantly, suggesting that sEVs may contain cargoes that promote the  
409 production of VEGF. We found that most of the sEVs are taken up by the non-  
410 cardiomyocytes. This could indicate an indirect effect on contractility, mediated by other  
411 cell types other than CMs, in particular ECs.

412 To confirm whether sEVs have a direct effect on CM contractility, we analysed calcium  
413 handling and contractility of iPSC-CMs monoculture. Physiological sEVs did not affect the  
414 contractility of iPSC-CMs nor the amplitude of calcium transients, suggesting that  
415 physiological sEVs may act on other cell types. Given the effect of physiological sEVs on LMS  
416 microvessels, we co-cultured iPSC-CMs with MVECs. In the co-culture experiments, despite  
417 no change in the calcium handling parameters, we observed a significant increase in  
418 contractility when physiological sEVs were applied. This suggests that changes in iPSC-CM  
419 contractility are: i) mediated by the effect of sEVs on ECs, and ii) due to changes in  
420 myofilament sensitivity to calcium. There are few limitations of these cellular experiments:  
421 although iPSC-CMs lines have been extensively used in cardiovascular research to  
422 recapitulate disease models, these cells are still very different from adult CMs, due to their  
423 relatively immature phenotype, and therefore it might not be a fully representative model  
424 to describe the changes in contractility that occur in the LMS<sup>52</sup>. Moreover, in our study

425 mechanical load is a major determinant of remodelling, but overload could not be recreated  
426 in iPSC-CMs.

427 If these results are extrapolated to the LMS model, whereby sEVs had a significant effect on  
428 contractility, preserved microvessel density and increased VEGF production, they may  
429 suggest that the beneficial effects of sEVs are indirect and mediated, at last in part, by ECs. It  
430 could be speculated that once sEVs (and their associated miRNAs) are taken up by ECs, they  
431 would release factors (such as VEGF) that improve CM contractility<sup>53</sup>. As example, miR-  
432 378a-3p was already shown to indirectly increase VEGF-A in skeletal muscles<sup>54</sup>.

### 433 **Conclusions**

434 Myocardial-specific sEVs from healthy human and rat hearts restore contractility and  
435 reverse/prevent remodelling of failing myocardium. The effects on contractility could be  
436 mediated by inhibition of cell death, inhibition of pro-fibrotic gene pathways or by  
437 preservation of blood vessels, or a combination of them, via indirect heterocellular  
438 interactions. The miRNA signature of the healthy sEVs may contribute to explain these  
439 effects. Our findings support the importance of sEVs in physiology and disease, and their  
440 potential utilisation in the treatment of cardiovascular disease.

### 441 **Acknowledgements:**

442 We would like to thank Steve Rothery for the support with confocal microscopy, Fatemeh  
443 Kermani for the gift of MVECs and Danya Agha-Jaffar for the support with the human tissue.  
444 We are grateful to the British Heart Foundation for financial support (FS/19/57/34894).

445

### 446 **Bibliography**

- 447 1. Katz AM. Maladaptive growth in the failing heart: the cardiomyopathy of overload.  
448 *Cardiovasc Drugs Ther.* 2002;16:245–249.
- 449 2. Martins-Marques T, Hausenloy DJ, Sluijter JPG, Leybaert L, Girao H. Intercellular  
450 Communication in the Heart: Therapeutic Opportunities for Cardiac Ischemia. *Trends Mol*  
451 *Med.* 2021;27:248–262.
- 452 3. Tirziu D, Giordano FJ, Simons M. Cell Communications in the Heart. *Circulation.*  
453 2010;122:928–937.
- 454 4. Jeppesen DK, Zhang Q, Franklin JL, Coffey RJ. Extracellular vesicles and nanoparticles:  
455 emerging complexities. *Trends Cell Biol.* 2023;33:667–681.
- 456 5. Davidson SM, Boulanger CM, Aikawa E, Badimon L, Barile L, Binder CJ, Brisson A, Buzas E,  
457 Emanuelli C, Jansen F, Katsur M, Lacroix R, Lim SK, Mackman N, Mayr M, Menasché P,  
458 Nieuwland R, Sahoo S, Takov K, Thum T, Vader P, Wauben MHM, Witwer K, Sluijter JPG.  
459 Methods for the identification and characterization of extracellular vesicles in cardiovascular  
460 studies: from exosomes to microvesicles. *Cardiovasc Res.* 2023;119:45–63.
- 461 6. Bellin G, Gardin C, Ferroni L, Chachques J, Rogante M, Mitrečić D, Ferrari R, Zavan B. Exosome  
462 in Cardiovascular Diseases: A Complex World Full of Hope. *Cells.* 2019;8:166.

- 463 7. Bang C, Batkai S, Dangwal S, Gupta SK, Foinquinos A, Holzmann A, Just A, Remke J, Zimmer K,  
464 Zeug A, Ponimaskin E, Schmiedl A, Yin X, Mayr M, Halder R, Fischer A, Engelhardt S, Wei Y,  
465 Schober A, Fiedler J, Thum T. Cardiac fibroblast-derived microRNA passenger strand-enriched  
466 exosomes mediate cardiomyocyte hypertrophy. *Journal of Clinical Investigation*.  
467 2014;124:2136–2146.
- 468 8. Zheng D, Huo M, Li B, Wang W, Piao H, Wang Y, Zhu Z, Li D, Wang T, Liu K. The Role of  
469 Exosomes and Exosomal MicroRNA in Cardiovascular Disease. *Front Cell Dev Biol*. 2021;8.
- 470 9. Vicencio JM, Yellon DM, Sivaraman V, Das D, Boi-Doku C, Arjun S, Zheng Y, Riquelme JA,  
471 Kearney J, Sharma V, Multhoff G, Hall AR, Davidson SM. Plasma Exosomes Protect the  
472 Myocardium From Ischemia-Reperfusion Injury. *J Am Coll Cardiol*. 2015;65:1525–1536.
- 473 10. Pant S, Hilton H, Burczynski ME. The multifaceted exosome: Biogenesis, role in normal and  
474 aberrant cellular function, and frontiers for pharmacological and biomarker opportunities.  
475 *Biochem Pharmacol*. 2012;83:1484–1494.
- 476 11. Watson SA, Scigliano M, Bardi I, Ascione R, Terracciano CM, Perbellini F. Preparation of viable  
477 adult ventricular myocardial slices from large and small mammals. *Nat Protoc*. 2017;12:2623–  
478 2639.
- 479 12. Perbellini F, Liu AKL, Watson SA, Bardi I, Rothery SM, Terracciano CM. Free-of-Acrylamide  
480 SDS-based Tissue Clearing (FASTClear) for three dimensional visualization of myocardial  
481 tissue. *Sci Rep*. 2017;7:5188.
- 482 13. Perbellini F, Watson SA, Scigliano M, Alayoubi S, Tkach S, Bardi I, Quaipe N, Kane C, Dufton NP,  
483 Simon A, Sikkell MB, Faggian G, Randi AM, Gorelik J, Harding SE, Terracciano CM. Investigation  
484 of cardiac fibroblasts using myocardial slices. *Cardiovasc Res*. 2018;114:77–89.
- 485 14. Watson SA, Duff J, Bardi I, Zabielska M, Atanur SS, Jabbour RJ, Simon A, Tomas A, Smolenski  
486 RT, Harding SE, Perbellini F, Terracciano CM. Biomimetic electromechanical stimulation to  
487 maintain adult myocardial slices in vitro. *Nat Commun*. 2019;10:2168.
- 488 15. Nunez-Toldra R, Kirwin T, Ferraro E, Pitoulis FG, Nicastro L, Bardi I, Kit-Anan W, Gorelik J,  
489 Simon AR, Terracciano CM. Mechanosensitive molecular mechanisms of myocardial fibrosis in  
490 living myocardial slices. *ESC Heart Fail*. 2022;9:1400–1412.
- 491 16. Pitoulis FG, Nunez-Toldra R, Xiao K, Kit-Anan W, Mitzka S, Jabbour RJ, Harding SE, Perbellini F,  
492 Thum T, de Tombe PP, Terracciano CM. Remodelling of adult cardiac tissue subjected to  
493 physiological and pathological mechanical load *in vitro*. *Cardiovasc Res*. 2022;118:814–827.
- 494 17. Andreu Z, Yáñez-Má M. Tetraspanins in Extracellular Vesicle Formation and Function.  
495 *Front Immunol*. 2014;5.
- 496 18. Grossman W, Paulus WJ. Myocardial stress and hypertrophy: a complex interface between  
497 biophysics and cardiac remodeling. *Journal of Clinical Investigation*. 2013;123:3701–3703.
- 498 19. Travers JG, Kamal FA, Robbins J, Yutzey KE, Blaxall BC. Cardiac Fibrosis. *Circ Res*.  
499 2016;118:1021–1040.
- 500 20. Wencker D, Chandra M, Nguyen K, Miao W, Garantziotis S, Factor SM, Shirani J, Armstrong  
501 RC, Kitsis RN. A mechanistic role for cardiac myocyte apoptosis in heart failure. *Journal of*  
502 *Clinical Investigation*. 2003;111:1497–1504.



- 503 21. Chaitanya GV, Alexander JS, Babu PP. PARP-1 cleavage fragments: Signatures of cell-death  
504 proteases in neurodegeneration. *Cell Communication and Signaling*. 2010;8.
- 505 22. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary  
506 Microvascular Rarefaction and Myocardial Fibrosis in Heart Failure With Preserved Ejection  
507 Fraction. *Circulation*. 2015;131:550–559.
- 508 23. Zeng H, Chen J-X. Microvascular Rarefaction and Heart Failure With Preserved Ejection  
509 Fraction. *Front Cardiovasc Med*. 2019;6.
- 510 24. Huebsch N, Loskill P, Mandegar MA, Marks NC, Sheehan AS, Ma Z, Mathur A, Nguyen TN, Yoo  
511 JC, Judge LM, Spencer CI, Chukka AC, Russell CR, So P-L, Conklin BR, Healy KE. Automated  
512 Video-Based Analysis of Contractility and Calcium Flux in Human-Induced Pluripotent Stem  
513 Cell-Derived Cardiomyocytes Cultured over Different Spatial Scales. *Tissue Eng Part C*  
514 *Methods*. 2015;21:467–479.
- 515 25. Oh JG, Lee P, Gordon RE, Sahoo S, Kho C, Jeong D. Analysis of extracellular vesicle miRNA  
516 profiles in heart failure. *J Cell Mol Med*. 2020;24:7214–7227.
- 517 26. Loyer X, Zlatanova I, Devue C, Yin M, Howangyin K-Y, Klaihmon P, Guerin CL, Kheloufi M, Vilar  
518 J, Zannis K, Fleischmann BK, Hwang DW, Park J, Lee H, Menasché P, Silvestre J-S, Boulanger  
519 CM. Intra-Cardiac Release of Extracellular Vesicles Shapes Inflammation Following Myocardial  
520 Infarction. *Circ Res*. 2018;123:100–106.
- 521 27. Sahoo S, Losordo DW. Exosomes and Cardiac Repair After Myocardial Infarction. *Circ Res*.  
522 2014;114:333–344.
- 523 28. Tanai E, Frantz S. Pathophysiology of Heart Failure. In: *Comprehensive Physiology*. Wiley;  
524 2015. p. 187–214.
- 525 29. Pitoulis F, Watson SA, Dries E, Bardi I, Nunez-Toldra R, Perbellini F, Terracciano CM.  
526 Myocardial Slices - A Novel Platform for In Vitro Biomechanical Studies. *Biophys J*.  
527 2019;116:30a.
- 528 30. Schwinger RH, Böhm M, Koch A, Schmidt U, Morano I, Eissner HJ, Uberfuhr P, Reichart B,  
529 Erdmann E. The failing human heart is unable to use the Frank-Starling mechanism. *Circ Res*.  
530 1994;74:959–969.
- 531 31. Stienen GJM. Pathomechanisms in heart failure: the contractile connection. *J Muscle Res Cell*  
532 *Motil*. 2015;36:47–60.
- 533 32. Nunez-Toldra R, Kirwin T, Ferraro E, Pitoulis FG, Nicastro L, Bardi I, Kit-Anan W, Gorelik J,  
534 Simon AR, Terracciano CM. Mechanosensitive molecular mechanisms of myocardial fibrosis in  
535 living myocardial slices. *ESC Heart Fail*. 2022;9:1400–1412.
- 536 33. Hutcherson JD, Aikawa E. Extracellular vesicles in cardiovascular homeostasis and disease. *Curr*  
537 *Opin Cardiol*. 2018;33:290–297.
- 538 34. Gupta S, Knowlton AA. HSP60 trafficking in adult cardiac myocytes: role of the exosomal  
539 pathway. *American Journal of Physiology-Heart and Circulatory Physiology*. 2007;292:H3052–  
540 H3056.



- 541 35. Tian C, Gao L, Zimmerman MC, Zucker IH. Myocardial infarction-induced microRNA-enriched  
542 exosomes contribute to cardiac Nrf2 dysregulation in chronic heart failure. *American Journal*  
543 *of Physiology-Heart and Circulatory Physiology*. 2018;314:H928–H939.
- 544 36. Wang Y, Xie Y, Zhang A, Wang M, Fang Z, Zhang J. Exosomes: An emerging factor in  
545 atherosclerosis. *Biomedicine & Pharmacotherapy*. 2019;115:108951.
- 546 37. Li N, Rochette L, Wu Y, Rosenblatt-Velin N. New Insights into the Role of Exosomes in the  
547 Heart After Myocardial Infarction. *J Cardiovasc Transl Res*. 2019;12:18–27.
- 548 38. Emanuelli C, Shearn AIU, Angelini GD, Sahoo S. Exosomes and exosomal miRNAs in  
549 cardiovascular protection and repair. *Vascul Pharmacol*. 2015;71:24–30.
- 550 39. Sahoo S, Adamiak M, Mathiyalagan P, Kenneweg F, Kafert-Kasting S, Thum T. Therapeutic and  
551 Diagnostic Translation of Extracellular Vesicles in Cardiovascular Diseases. *Circulation*.  
552 2021;143:1426–1449.
- 553 40. Ganesan J, Ramanujam D, Sassi Y, Ahles A, Jentzsch C, Werfel S, Leierseder S, Loyer X, Giacca  
554 M, Zentilin L, Thum T, Laggerbauer B, Engelhardt S. MiR-378 Controls Cardiac Hypertrophy by  
555 Combined Repression of Mitogen-Activated Protein Kinase Pathway Factors. *Circulation*.  
556 2013;127:2097–2106.
- 557 41. Oikawa S, Wada S, Lee M, Maeda S, Akimoto T. Role of endothelial microRNA-23 clusters in  
558 angiogenesis in vivo. *American Journal of Physiology-Heart and Circulatory Physiology*.  
559 2018;315:H838–H846.
- 560 42. Xing Y, Hou J, Guo T, Zheng S, Zhou C, Huang H, Chen Y, Sun K, Zhong T, Wang J, Li H, Wang T.  
561 microRNA-378 promotes mesenchymal stem cell survival and vascularization under hypoxic–  
562 ischemic conditions in vitro. *Stem Cell Res Ther*. 2014;5:130.
- 563 43. Tan J, Shen J, Zhu H, Gong Y, Zhu H, Li J, Lin S, Wu G, Sun T. miR-378a-3p inhibits  
564 ischemia/reperfusion-induced apoptosis in H9C2 cardiomyocytes by targeting TRIM55 via the  
565 DUSP1-JNK1/2 signaling pathway. *Aging*. 2020;12:8939–8952.
- 566 44. Wu F, Wang F, Yang Q, Zhang Y, Cai K, Liu L, Li S, Zheng Y, Zhang J, Gui Y, Wang Y, Wang X, Gui  
567 Y, Li Q. Upregulation of miRNA-23a-3p rescues high glucose-induced cell apoptosis and  
568 proliferation inhibition in cardiomyocytes. *In Vitro Cell Dev Biol Anim*. 2020;56:866–877.
- 569 45. O’Brien J, Hayder H, Zayed Y, Peng C. Overview of microRNA biogenesis, mechanisms of  
570 actions, and circulation. *Front Endocrinol (Lausanne)*. 2018;9.
- 571 46. Kehat I, Molkenin JD. Molecular Pathways Underlying Cardiac Remodeling During  
572 Pathophysiological Stimulation. *Circulation*. 2010;122:2727–2735.
- 573 47. Pitoulis FG, Terracciano CM. Heart Plasticity in Response to Pressure- and Volume-Overload:  
574 A Review of Findings in Compensated and Decompensated Phenotypes. *Front Physiol*.  
575 2020;11.
- 576 48. Gobeil S, Boucher CC, Nadeau D, Poirier GG. Characterization of the necrotic cleavage of  
577 poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. *Cell Death Differ*.  
578 2001;8:588–594.
- 579 49. Luxán G, Dimmeler S. The vasculature: a therapeutic target in heart failure? *Cardiovasc Res*.  
580 2022;118:53–64.

- 581 50. Brutsaert DL. Cardiac Endothelial-Myocardial Signaling: Its Role in Cardiac Growth, Contractile  
582 Performance, and Rhythmicity. *Physiol Rev.* 2003;83:59–115.
- 583 51. Ahmed RE, Anzai T, Chanthra N, Uosaki H. A Brief Review of Current Maturation Methods for  
584 Human Induced Pluripotent Stem Cells-Derived Cardiomyocytes. *Front Cell Dev Biol.* 2020;8.
- 585 52. Hua Z, Lv Q, Ye W, Wong CKA, Cai G, Gu D, Ji Y, Zhao C, Wang J, Yang BB, Zhang Y. Mirna-  
586 directed regulation of VEGF and other angiogenic under hypoxia. *PLoS One.* 2006;1.
- 587 53. Krist B, Podkalicka P, Mucha O, Mendel M, Sępioł A, Rusiecka OM, Józefczuk E, Bukowska-  
588 Strakova K, Grochot-Przęczek A, Tomczyk M, Klóska D, Giacca M, Maga P, Niżankowski R,  
589 Józkwicz A, Łoboda A, Dulak J, Florczyk-Soluch U. miR-378a influences vascularization in  
590 skeletal muscles. *Cardiovasc Res.* 2020;116:1386–1397.

591

## 592 **Figure legends**

593 **Figure 1. Characterization of human LMS contractility and human LMS-derived sEVs. A.**  
594 Representative traces of produced force of donor and failing LMS at 25% stretch. **B.** Active  
595 force and **C.** passive force of human donor and failing hearts after 48 hours culture. N=6  
596 Donors and N=9 Failing. Data are presented as mean $\pm$  SEM. Multiple unpaired t-tests.  
597 \*P<0.05. **D.** Particle size distribution of failing and donor sEVs. N=3 donor sEVs and N=6  
598 failing sEVs. Unpaired t-test. \*\*\*P<0.001. **E.** Nanoview representative image of nanoparticle  
599 analysis of failing human sEVs. CD63 (red), CD81 (green), CD9 (blue) and **F.** Transmission  
600 electron microscopy with CD63 immunogold labelling of human donor sEVs (left panel) and  
601 zoomed in view (right panel).

602 **Figure 2. Human donor sEVs significantly increase the active force produced by human**  
603 **failing slices at physiological load. A.** Representative traces of the force generated by failing  
604 slices treated with donor sEVs and control. **B.** Active force and **C.** Passive force of the force-  
605 stretch relationship of human failing slices treated with donor sEVs. N=5 Failing, N=5  
606 Failing+Donor sEVs. For each N, the force-stretch measurements of 3-4 LMS were averaged.  
607 Data are presented as mean  $\pm$  SEM. Multiple paired t-tests. \*P<0.05.

608 **Figure 3. Characterization of rat LMS contractility and rat LMS-derived sEVs. A. .**  
609 Representative images of rat slices stretched at 2.2 and 2.4  $\mu$ m of SL to recapitulate  
610 physiological load and overload, respectively (created in BioRender.com). **B.** Representative  
611 trace of contractility of physiological and overloaded slices at 25% stretch. **C.** active force  
612 and **D.** passive force of rat physiological and overloaded slice after 48 hours culture. Data are  
613 presented as mean  $\pm$  SEM. N=28 physiological and N=19 overloaded slices. 2-Way-ANOVA  
614 analysis with Šídák's multiple comparisons test. \*P<0.05; \*\*P<0.01. **E.** Particle size  
615 distribution of physiological and overloaded EVs from rat slices. N=16 physiological EVs and  
616 N=8 overloaded EVs. Unpaired t-test. **F.** Quantification of internal protein content of EVs  
617 from physiological and overloaded slices from rat slices. Data are presented as mean  $\pm$ /  
618 SEM. Unpaired t-test. \*P<0.05. **G.** Transmission electron microscopy with CD63 immunogold  
619 labelling rat physiological EVs (left panel) and zoomed in view (right panel).

620 **Figure 4. The effect of cardiac sEVs on the force generation of rat living myocardial slices.**  
621 **A.** Representative traces of physiological slices treated with physiological sEVs, overloaded  
622 sEVs and control. **B.** Active force and **C.** Passive force of the force stretch relationship of rat  
623 physiological slices treated with physiological sEVs, overloaded sEVs or control (PBS only).  
624 N=33 PBS treated LMS, N=11 Physiological sEVs LMS, N=14 Overloaded sEVs LMS. Data are  
625 presented as mean +/- SEM. 2-Way ANOVA with Tukey's multiple comparisons test. \*P<0.05  
626 and \*\*P<0.01 for PBS only vs physiological sEVs, ^P<0.01 Physiological sEVs vs overloaded  
627 sEVs. **D.** Representative traces of dose-response experiments. **E.** Active force and **F.** Passive  
628 force of the force stretch relationship of rat overloaded slices treated with 10<sup>7</sup>, 10<sup>8</sup>, 10<sup>9</sup>,  
629 10<sup>10</sup> sEVs per slices, or control (overloaded). N=19 overloaded, N= 7 10<sup>7</sup>, N= 11 10<sup>8</sup>,  
630 N=16 10<sup>9</sup>, N=3 10<sup>10</sup>. Data are presented as mean +/- SEM. 2-Way ANOVA with Tukey's  
631 multiple comparisons test. \*P<0.05 overloaded vs 10<sup>9</sup> sEVs, ^P<0.01 overloaded vs  
632 10<sup>8</sup> sEVs, ##P<0.01 overloaded vs 10<sup>10</sup> sEVs.

633 **Figure 5. The effect of physiological sEVs on the fibrosis of overloaded slices. Figure 5. A.**  
634 Representative images of physiological, overloaded and overloaded + sEVs slices stained for  
635 Caveolin 3, Vimentin and Collagen I. Scale bar 50 μm. Quantification of immunofluorescence  
636 staining of **B.** Vimentin and **C.** Collagen I. Data are presented as mean +/- SEM. One-Way  
637 ANOVA with Tukey's multiple comparisons test.. **D.** Western Blot quantification of Collagen I  
638 expression in physiological, overloaded and overloaded slices+sEVs. One-Way ANOVA with  
639 Tukey's multiple comparisons test. **E.** Western Blot quantification of α-SMA expression in  
640 physiological, overloaded and overloaded + sEVs slices. Data are presented as mean +/- SEM.  
641 One-Way ANOVA with Tukey's multiple comparisons test. **F.** mRNA quantification of the  
642 expression of major pro-fibrotic markers in physiological, overloaded and overloaded + sEVs  
643 slices. Data are presented as mean +/- SEM. One-Way ANOVA with Tukey's multiple  
644 comparisons test. =P<0.05, \*\*p<0.01.

645  
646 **Figure 6. The effect of physiological sEVs on the apoptosis of overloaded slices. A.** Western  
647 Blot quantification of PARP-1 expression in physiological, overloaded and overloaded + sEVs  
648 slices. One-Way ANOVA with Tukey's multiple comparisons test. \*P<0.05, \*\*P<0.01. **B.**  
649 Western Blot quantification of Bcl-2 expression in physiological, overloaded and overloaded  
650 + sEVs slices. One-Way ANOVA with Tukey's multiple comparisons test. \*\*P<0.01. **C.**  
651 Quantification of immunofluorescence staining of TUNEL assay in physiological, overloaded  
652 and overloaded slices+ sEVs. Slices were stained with DAPI, Isolectin B4, TUNEL and WGA.  
653 One-Way ANOVA with Tukey's multiple comparisons test. \*P<0.05. Scale bar 50 μm.

654  
655 **Figure 7. The effect of physiological sEVs on the blood vessel rarefaction in overloaded**  
656 **slices. A.** Quantification of Isolectin B4 immunostaining in physiological, overloaded and  
657 overloaded slices + sEVs. Scale bar 50 μm. Data are presented as mean +/- SEM. One-Way  
658 ANOVA with Tukey's multiple comparisons test. \*\*P<0.01, \*\*\*\*P<0.0001. **B.** Quantification  
659 of VEGF gene expression by qPCR in physiological, overloaded and overloaded + sEVs slices.  
660 Data are presented as mean +/- SEM. One-Way ANOVA with Tukey's multiple comparisons  
661 test. over physiological slices. \*P<0.05. Data are expressed as fold change expression.

662 **Figure 8. The effect of physiological sEVs on iPSC-CMs and on iPSC-CMs cultured with**  
663 **microvasculature endothelial cells. A.** Representative traces of calcium transients in iPSC-

664 CMs treated with physiological sEVs and control. **B.** Representative traces of contractility in  
665 iPSC-CMs treated with physiological sEVs and control **C.** Amplitude **D.** Time to peak **E.** Time  
666 to 50% decay and **F.** Time to 80% decay of calcium transients and **G.** amplitude of  
667 contractility in iPSC-CMs treated with rat physiological sEVs or control. Unpaired t-test.  
668  $*=P<0.05$ . **H.** Representative traces of calcium transient amplitude in iPSC-CMs and  
669 microvasculature ECs co-culture treated with physiological sEVs and control. **I.**  
670 Representative traces of contractility in iPSC-CMs and microvasculature ECs co-culture  
671 treated with physiological sEVs and control **J.** Amplitude **K.** Time to peak **L.** Time to 50%  
672 decay and **M.** Time to 80% decay of calcium transients and **N.** amplitude of contractility in  
673 iPSC-CMs co-cultured with microvasculature endothelial cells treated with rat physiological  
674 sEVs or control. Data are presented as mean +/- SEM. Unpaired t-test.  $*P<0.05$ .

**Figure 1**






Figure 2

A



B



C







Figure 3

A

Physiological  
2.2  $\mu\text{m}$  SL

Overloaded  
2.4  $\mu\text{m}$  SL




17.5 % stretch




27.3 % stretch

B


— Physiological  
— Overloaded




C




D




E




F




G



**Figure 4**



**Figure 5**



**Figure 6**








Figure 7

A



B VEGF-A



**Figure 8**